Regeneron Pharmaceuticals Inc (REGN) : Deimos Asset Management added new position in Regeneron Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 8,500 shares of Regeneron Pharmaceuticals Inc which is valued at $3,583,090 , the company said in a statement filed on Aug 12, 2016 with the SEC.Regeneron Pharmaceuticals Inc makes up approximately 2.99% of Deimos Asset Management’s portfolio.
Other Hedge Funds, Including , Raymond James Financial Services Advisors reduced its stake in REGN by selling 947 shares or 18.81% in the most recent quarter. The Hedge Fund company now holds 4,087 shares of REGN which is valued at $1,722,834. Regeneron Pharmaceuticals Inc makes up approx 0.02% of Raymond James Financial Services Advisors’s portfolio.State Of Wisconsin Investment Board reduced its stake in REGN by selling 4,100 shares or 7.61% in the most recent quarter. The Hedge Fund company now holds 49,800 shares of REGN which is valued at $20,992,692. Regeneron Pharmaceuticals Inc makes up approx 0.08% of State Of Wisconsin Investment Board’s portfolio. Bsw Wealth Partners sold out all of its stake in REGN during the most recent quarter. The investment firm sold 684 shares of REGN which is valued $288,333.Public Sector Pension Investment Board boosted its stake in REGN in the latest quarter, The investment management firm added 2,100 additional shares and now holds a total of 14,797 shares of Regeneron Pharmaceuticals Inc which is valued at $6,237,527. Regeneron Pharmaceuticals Inc makes up approx 0.08% of Public Sector Pension Investment Board’s portfolio. Moody Lynn Lieberson sold out all of its stake in REGN during the most recent quarter. The investment firm sold 5,905 shares of REGN which is valued $2,510,334.
Regeneron Pharmaceuticals Inc closed down -3.59 points or -0.89% at $399.38 with 5,54,880 shares getting traded on Monday. Post opening the session at $405.15, the shares hit an intraday low of $396.58 and an intraday high of $405.99 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.65. The company had revenue of $1213.00 million for the quarter, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Shares were Downgraded by Robert W. Baird on Aug 5, 2016 to ” Neutral” and Lowered the Price Target to $ 448 from a previous price target of $505 .Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.